[Non-identified antinuclear antibodies in systemic sclerosis].

Area of Science:

• Immunology
• Rheumatology
• Autoimmune Diseases

Background:

• Systemic sclerosis is a rare autoimmune disease affecting skin and potentially internal organs.
• Anti-nuclear antibodies (ANA) are present in 95% of patients, commonly anti-topoisomerase 1 (anti-Scl 70) and anti-centromeres.
• Many "non-identified" ANA are not routinely tested in clinical practice.

Purpose of the Study:

• To identify "non-identified" ANA in a cohort of systemic sclerosis patients at Erasme Hospital.
• To determine the prevalence of these antibodies within the cohort.
• To correlate the presence of identified antibodies with specific clinical characteristics of scleroderma.

Main Methods:

• Analyzed clinical and biological data from 89 systemic sclerosis patients.
• Employed immunodot and EliA techniques for antibody detection.
• Compared results with established clinical and serological data.

Main Results:

• 17 out of 89 patients (19.1%) had "non-identified" ANA.
• Immunodot identified anti-PmScl (75 and/or 100), RNA polymerase III, and antifibrillarin antibodies.
• EliA detected anti-PmScl, anti-RNA polymerase, anti-fibrillarin, and anti-centromere antibodies in a subset of patients.
• Specific antibody correlations with clinical features were observed.

Conclusions:

• Autoantibodies beyond anti-topoisomerase and anti-centromere are present in systemic sclerosis patients.
• A correlation exists between specific autoantibodies and clinical manifestations of the disease.
• The search for novel autoantibodies in scleroderma, especially in antibody-negative cases, remains ongoing.